In 2019, Kim suggested using a plasma APE1/Ref-1 level > 0.202 ng/mL (sensitivity: 82.5; specificity: 97.4) as a diagnostic criterion to differentiate patients with clear cell renal cell cancer from healthy people [23]. The gene discussed is APEX1; the disease is clear cell renal carcinoma.